文献速递治疗药物监测与药物基因组学特殊人群用药

伏立康唑模型引导精准给药的现实世界验证

Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data.
PubMed 文献 · Clin Pharmacokinet · 2023-08-21

本研究利用包含九项伏立康唑研究的院内临床数据库,外部评估已发表的非线性混合效应模型,并比较聚合模型与两个标准模型的预测性能。结果显示聚合模型预测性能最佳但所有模型仅中等,纳入近期伏立康唑监测数据可显著改善预测。

要点

  • 聚合模型在伏立康唑MIPD中预测性能最佳。
  • 所有评估模型预测性能仅中等,结构模型和变异来源可能不足。
  • 纳入近期伏立康唑TDM观测值可显著提升预测性能。

核心结论

  • 聚合模型在外部评估中预测性能最佳,但所有伏立康唑NLME模型预测性能仅中等。
  • 将近期伏立康唑观测值纳入贝叶斯预测可显著改善模型预测性能。

研究设计与样本

  • 研究采用外部评估方法,使用包含九项伏立康唑研究的院内临床数据库。
  • 比较一个聚合模型(整合六个已发表NLME模型特征与先验信息)与两个标准NLME模型,并应用不同贝叶斯预测策略。

主要发现

  • 所有NLME模型预测性能仅中等,提示重要PK过程未充分实现、个体间变异来源未完全捕捉、场合间变异未充分考量。
  • 纳入最近一次伏立康唑观测值后,模型预测性能显著改善。

临床怎么用

  • 伏立康唑MIPD应优先考虑聚合模型,并纳入近期TDM观测值进行贝叶斯预测。
  • 在临床使用复杂PK药物MIPD前,需基于全面临床数据库进行仔细的外部模型评估。

局限性

  • 所有评估模型预测性能仅中等,结构模型和变异来源可能存在不足。
  • 研究基于特定院内数据库,模型外推性需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Model-informed precision dosing (MIPD) frequently uses nonlinear mixed-effects (NLME) models to predict and optimize therapy outcomes based on patient characteristics and therapeutic drug monitoring data. MIPD is indicated for compounds with narrow therapeutic range and complex pharmacokinetics (PK), such as voriconazole, a broad-spectrum antifungal drug for prevention and treatment of invasive fungal infections. To provide guidance and recommendations for evidence-based application of MIPD for voriconazole, this work aimed to (i) externally evaluate and compare the predictive performance of a published so-called 'hybrid' model for MIPD (an aggregate model comprising features and prior information from six previously published NLME models) versus two 'standard' NLME models of voriconazole, and (ii) investigate strategies and illustrate the clinical impact of Bayesian forecasting for voriconazole. METHODS: A workflow for external evaluation and application of MIPD for voriconazole was implemented. Published voriconazole NLME models were externally evaluated using a comprehensive in-house clinical database comprising nine voriconazole studies and prediction-/simulation-based diagnostics. The NLME models were applied using different Bayesian forecasting strategies to assess the influence of prior observations on model predictivity. RESULTS: The overall best predictive performance was obtained using the aggregate model. However, all NLME models showed only modest predictive performance, suggesting that (i) important PK processes were not sufficiently implemented in the structural submodels, (ii) sources of interindividual variability were not entirely captured, and (iii) interoccasion variability was not adequately accounted for. Predictive performance substantially improved by including the most recent voriconazole observations in MIPD. CONCLUSION: Our results highlight the potential clinical impact of MIPD for voriconazole and indicate the need for a comprehensive (pre-)clinical database as basis for model development and careful external model evaluation for compounds with complex PK before their successful use in MIPD.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Kluwe F, Michelet R, Huisinga W, et al. Towards Model-Informed Precision Dosing of Voriconazole: Challenging Published Voriconazole Nonlinear Mixed-Effects Models with Real-World Clinical Data. Clin Pharmacokinet. 2023. PMID: 37603216. doi:10.1007/s40262-023-01274-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。